BioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for Agitation

BTAI Stock  USD 0.43  0.01  2.27%   
Under 66% of BioXcel Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding BioXcel Therapeutics suggests that many traders are alarmed. BioXcel Therapeutics' investing sentiment shows overall attitude of investors towards BioXcel Therapeutics.
  
Recently initiated SERENITY At-Home pivotal Phase 3 trial for agitation associated with bipolar disorders or schizophrenia Submitted protocol to FDA for TRANQUILITY In-Care pivotal Phase 3 trial for agitation associated with Alzheimers dementia Company to maintain IGALMI in the market without current commercial infrastructure NEW HAVEN, Conn., Sept. 19, 2024 -- BioXcel Therapeutics, Inc. , a biopharmaceutical company utilizing artificial intelligence to develop

Read at finance.yahoo.com
Yahoo News
  

BioXcel Therapeutics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards BioXcel Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

BioXcel Therapeutics Fundamental Analysis

We analyze BioXcel Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioXcel Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioXcel Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Current Valuation

Current Valuation Comparative Analysis

BioXcel Therapeutics is currently under evaluation in current valuation category among its peers. Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

BioXcel Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with BioXcel Therapeutics stock to make a market-neutral strategy. Peer analysis of BioXcel Therapeutics could also be used in its relative valuation, which is a method of valuing BioXcel Therapeutics by comparing valuation metrics with similar companies.

Peers

BioXcel Therapeutics Related Equities

XFORX4 Pharmaceuticals   13.43   
0%
100.0%
VKTXViking Therapeutics   2.84   
0%
21.0%
EXELExelixis   0.54   
0%
4.0%
ABOSAcumen Pharmaceuticals   0.46   
0%
3.0%
TGTXTG Therapeutics   0.06   
1.0%
0%
MREOMereo BioPharma   0.26   
1.0%
0%
DAWNDay One   0.45   
3.0%
0%
INZYInozyme Pharma   0.67   
4.0%
0%
APLSApellis Pharmaceuticals   1.85   
13.0%
0%
MDGLMadrigal Pharmaceuticals   1.99   
14.0%
0%
AMLXAmylyx Pharmaceuticals   3.10   
23.0%
0%
TERNTerns Pharmaceuticals   3.18   
23.0%
0%
ELEVElevation Oncology   4.00   
29.0%
0%
HEPAHepion Pharmaceuticals   6.35   
47.0%
0%

Complementary Tools for BioXcel Stock analysis

When running BioXcel Therapeutics' price analysis, check to measure BioXcel Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioXcel Therapeutics is operating at the current time. Most of BioXcel Therapeutics' value examination focuses on studying past and present price action to predict the probability of BioXcel Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioXcel Therapeutics' price. Additionally, you may evaluate how the addition of BioXcel Therapeutics to your portfolios can decrease your overall portfolio volatility.
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets